BioXcel Therapeutics Updates on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI (Dexmedetomidine) Sublingual Film
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has provided an update on its late-stage clinical programs and its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film. The company has scheduled meetings with the FDA to discuss the TRANQUILITY and SERENITY III clinical programs and has received two Notices of Allowance from the U.S. Patent and Trademark Office to extend method of use patent protection for sublingual dexmedetomidine.
October 04, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics' late-stage clinical programs and patent portfolio for IGALMI are progressing, with meetings scheduled with the FDA and two Notices of Allowance received to extend patent protection.
The company's progress in its late-stage clinical programs and the extension of its patent protection for IGALMI could potentially lead to positive outcomes, such as approval of its products and protection of its intellectual property. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100